Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELUT Stock Forecast 2025-2026
$1.72
Current Price
$70.29M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELUT Price Targets
+365.1%
To High Target of $8.00
+336.0%
To Median Target of $7.50
+307.0%
To Low Target of $7.00
ELUT Price Momentum
-17.3%
1 Week Change
-18.1%
1 Month Change
-46.6%
1 Year Change
-54.0%
Year-to-Date Change
-67.2%
From 52W High of $5.24
+1.8%
From 52W Low of $1.69
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Elutia (ELUT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ELUT and similar high-potential opportunities.
Latest ELUT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ELUT has a bullish consensus with a median price target of $7.50 (ranging from $7.00 to $8.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.72, the median forecast implies a 336.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 365.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELUT Analyst Ratings
2
Buy
0
Hold
0
Sell
ELUT Price Target Range
Low
$7.00
Average
$7.50
High
$8.00
Current: $1.72
Latest ELUT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELUT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Mar 7, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $10.00 |
| Sep 6, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $10.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $10.00 |
| Jun 21, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $10.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $11.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $11.00 |
| May 10, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $5.00 |
| Nov 14, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $6.00 |
| Sep 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Sep 19, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Aug 15, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $0.00 | |
| May 12, 2023 | Cantor Fitzgerald | Brandon Folkes | Overweight | Maintains | $10.00 |
| Nov 16, 2022 | Truist Securities | Kaila Krum | Buy | Maintains | $10.00 |
| Nov 15, 2022 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $10.50 |
| Mar 4, 2022 | Cowen & Co. | Josh Jennings | Outperform | Maintains | $13.00 |
| Nov 2, 2020 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Nov 2, 2020 | Piper Sandler | Overweight | Initiates | $0.00 |
Elutia Inc. (ELUT) Competitors
The following stocks are similar to Elutia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elutia Inc. (ELUT) Financial Data
Elutia Inc. has a market capitalization of $70.29M with a P/E ratio of 0.0x. The company generates $23.71M in trailing twelve-month revenue with a -168.2% profit margin.
Revenue growth is -9.9% quarter-over-quarter, while maintaining an operating margin of -88.7% and return on equity of +116.6%.
Valuation Metrics
Market Cap
$70.29M
Enterprise Value
$74.08M
P/E Ratio
0.0x
PEG Ratio
-1.6x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
-9.9%
Gross Margin
+42.5%
Operating Margin
-88.7%
Net Margin
-168.2%
EPS Growth
-6.9%
Financial Health
Cash/Price Ratio
+26.2%
Current Ratio
0.8x
Debt/Equity
-0.5x
ROE
+116.6%
ROA
-38.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Elutia Inc. (ELUT) Business Model
About Elutia Inc.
What They Do
Develops drug-eluting biomaterials for targeted therapies.
Business Model
Elutia Inc. focuses on creating and commercializing innovative biomaterials that deliver pharmaceuticals directly to targeted tissues. The company generates revenue through the sale of these specialized products, which are utilized in various medical fields such as wound care, cardiovascular treatments, and orthopedics.
Additional Information
Operating at the forefront of biotechnology and precision medicine, Elutia Inc. is committed to improving patient outcomes through advanced therapeutic solutions. The company is well-positioned in the healthcare industry, emphasizing innovation in drug delivery systems that meet the evolving needs of modern medicine.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
51
CEO
Dr. C. Randal Mills Ph.D.
Country
United States
IPO Year
2020
Website
elutia.comElutia Inc. (ELUT) Latest News & Analysis
Latest News
Quick Summary
Elutia Inc. (NASDAQ: ELUT) will hold its Q1 2025 earnings conference call on May 8, 2025, at 5:00 PM ET, featuring CEO Randal Mills and CFO Matt Ferguson.
Why It Matters
Elutia's Q1 2025 earnings call indicates upcoming financial performance insights, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Boston Scientific has announced a new distribution partnership and will hold a conference call today at 5:00 p.m. ET to discuss details.
Why It Matters
A new distribution partnership for Boston Scientific can enhance market reach and revenue potential, impacting stock performance and investor sentiment. Conference call may provide crucial insights.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. (Nasdaq: ELUT) will release its Q1 2025 financial results on May 8, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters
Elutia's upcoming financial results and conference call can influence stock performance, as investors assess growth and financial health based on earnings and management insights.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. is reclaiming U.S. sales and distribution for its cardiovascular products after ending its agreement with LeMaitre Vascular, aiming to enhance top-line revenue and gross margins.
Why It Matters
Elutia's reclaiming of U.S. sales for its cardiovascular products enhances revenue control and profitability, likely leading to improved financial performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. has initiated a clinical study for its EluPro™ technology to gather patient-reported outcomes in CIED procedures, enhancing its differentiation in the market.
Why It Matters
The integration of clinical and patient-reported outcomes for EluPro may enhance its market position in CIED procedures, potentially driving demand and revenue for Elutia Inc.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29
23 days ago
Quick Summary
Elutia Inc. (Nasdaq: ELUT) announced that Dr. Michelle LeRoux Williams, its Chief Scientific Officer, will speak at Chardan's Drug Development Conference on April 29, 2025.
Why It Matters
Elutia's participation in a prominent conference highlights its innovation in drug-eluting technologies, potentially boosting investor confidence and market interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ELUT Stock
What is Elutia Inc.'s (ELUT) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Elutia Inc. (ELUT) has a median price target of $7.50. The highest price target is $8.00 and the lowest is $7.00.
Is ELUT stock a good investment in 2025?
According to current analyst ratings, ELUT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELUT stock?
Wall Street analysts predict ELUT stock could reach $7.50 in the next 12 months. This represents a 336.0% increase from the current price of $1.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elutia Inc.'s business model?
Elutia Inc. focuses on creating and commercializing innovative biomaterials that deliver pharmaceuticals directly to targeted tissues. The company generates revenue through the sale of these specialized products, which are utilized in various medical fields such as wound care, cardiovascular treatments, and orthopedics.
What is the highest forecasted price for ELUT Elutia Inc.?
The highest price target for ELUT is $8.00 from Frank Takkinen at Lake Street, which represents a 365.1% increase from the current price of $1.72.
What is the lowest forecasted price for ELUT Elutia Inc.?
The lowest price target for ELUT is $7.00 from at , which represents a 307.0% increase from the current price of $1.72.
What is the overall ELUT consensus from analysts for Elutia Inc.?
The overall analyst consensus for ELUT is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are ELUT stock price projections?
Stock price projections, including those for Elutia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 15, 2025 11:02 PM UTC